Emicizumab and asparaginase, A first experience to share

Haemophilia. 2024 Mar;30(2):561-563. doi: 10.1111/hae.14935. Epub 2024 Jan 19.

Authors

Laurie Goubeau¹, Cécile Bally², Delphine Borgel^{1

3}, Fanny Alby-Laurent⁴, Arnaud Petit⁴, Laurent Frenzel², Dominique Lasne^{1

3}, Annie Harroche²

Affiliations

¹ Laboratoire d'Hématologie Biologique, AP-HP, Hôpital Necker Enfants Malades, Paris, France.
² Centre de Traitement de l'Hémophilie, AP-HP, Hôspital Necker Enfants Malades, Paris, France.
³ HITh, UMR_S 1176, INSERM, Univ. Paris-Saclay, Le Kremlin-Bicêtre, France.
⁴ Service d'hématologie pédiatrique, AP-HP, Hôpital Trousseau, Paris, France.

PMID: 38240017
DOI: 10.1111/hae.14935

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Bispecific*
Antibodies, Monoclonal, Humanized
Asparaginase
Factor VIII
Hemophilia A*
Humans

Substances

emicizumab
Asparaginase
Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
Factor VIII